7 March 2022 - Diurnal provides an update on the status of reimbursement of Efmody (modified release hydrocortisone) for NHS Scotland.

The Company notes that, while Efmody remains available to prescribe in Scotland, the Scottish Medicines Consortium has today announced that Efmody has not been recommended for automatic reimbursement within NHS Scotland as a treatment of congenital adrenal hyperplasia in adolescents aged 12 years and over and adults. 

Diurnal will generate further clinical and health economic data to support a re submission to the SMC at the earliest possible opportunity.

Read Diurnal press release